Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.41 |
| ▸ | RXRA | P19793 | 1/20 | 0.40 |
| ▸ | RXRB | P28702 | 1/20 | 0.40 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.39 |
| ▸ | LPL | P06858 | 1/20 | 0.39 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | SOD1 | P00441 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18927002 | 0.81 | SMN1; SMN2 (0.46) | SMN1; SMN2CYP2C19TP53ALDH1A1LMNA | |
| SCHEMBL3289628 | 0.81 | THRB (0.47) | ALDH1A1LMNATAAR1LPLLIPG | |
| SCHEMBL769086 | 0.78 | CA2 (0.47) | SMN1; SMN2TP53ALDH1A1LMNAMAPT | |
| SCHEMBL2334725 | 0.76 | IDO1 (0.43) | SMN1; SMN2TAAR1RAB9ANPC1 | |
| SCHEMBL1509992 | 0.76 | ALDH1A1 (0.52) | SMN1; SMN2TP53ALDH1A1LMNAMAPT | |
| SCHEMBL16117387 | 0.76 | SMN1; SMN2 (0.42) | SMN1; SMN2CYP2C19ALDH1A1LMNAMAPT | |
| SCHEMBL475215 | 0.76 | SMN1; SMN2 (0.48) | SMN1; SMN2CYP2C19TP53ALDH1A1LMNA | |
| SCHEMBL8925998 | 0.76 | SMN1; SMN2 (0.48) | SMN1; SMN2CYP2C19TP53ALDH1A1LMNA | |
| SCHEMBL11725689 | 0.76 | TAAR1 (0.52) | SMN1; SMN2CYP2C19TP53ALDH1A1LMNA | |
| SCHEMBL27927558 | 0.75 | TAAR1 (0.46) | SMN1; SMN2CYP2C19TP53ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 195 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4263677-B1 | METHODS AND SYSTEMS FOR PRODUCTION OF FURFURAL | SHELL INT RESEARCH (NL) | 2024-10-30 | — | — | EP | claimed |
| EP-4263676-B1 | METHODS AND SYSTEMS FOR PRODUCTION OF FURFURAL | SHELL INT RESEARCH (NL) | 2024-10-30 | — | — | EP | claimed |
| US-20240025871-A1 | METHODS AND SYSTEMS FOR PRODUCTION OF FURFURAL | SHELL USA, INC. | 2024-01-25 | — | — | US | claimed |
| EP-4263676-A1 | METHODS AND SYSTEMS FOR PRODUCTION OF FURFURAL | Shell Internationale Research Maatschappij B.V. (NL) | 2023-10-25 | — | — | EP | claimed |
| EP-4263677-A1 | METHODS AND SYSTEMS FOR PRODUCTION OF FURFURAL | Shell Internationale Research Maatschappij B.V. (NL) | 2023-10-25 | — | — | EP | claimed |
| WO-2022133271-A1 | METHODS AND SYSTEMS FOR PRODUCTION OF FURFURAL | SHELL OIL COMPANY (US) | 2022-06-23 | — | — | WO | claimed |
| WO-2022133243-A1 | METHODS AND SYSTEMS FOR PRODUCTION OF FURFURAL | SHELL OIL COMPANY (US) | 2022-06-23 | — | — | WO | claimed |
| US-20220194914-A1 | METHODS AND SYSTEMS FOR PRODUCTION OF FURFURAL | SHELL OIL COMPANY | 2022-06-23 | — | — | US | claimed |
| CN-111362805-A | Method for synthesizing biphenyl compounds by taking phenol as raw material | 遵义医科大学 | 2020-07-03 | — | — | CN | claimed |
| CN-111253234-A | Method for synthesizing biphenyl compounds by taking suaeda salsa extract liquid as solvent | 遵义医科大学 | 2020-06-09 | — | — | CN | claimed |
| US-20250282735-A1 | BICYCLE COMPOUNDS AS TEAD INHIBITOR | DONG-A ST CO., LTD. (KR) | 2025-09-11 | — | — | US | disclosed |
| US-20250092058-A1 | MATTER OF COMPOSITION, SYNTHESIS, FORMULATION AND APPLICATION OF FL 118 PLATFORM POSITIONS 7 AND 9-DERIVED ANALOGUES FOR TREATMENT OF HUMAN DISEASE | CANGET BIOTEKPHARMA, LLC | 2025-03-20 | — | — | US | disclosed |
| CN-114555594-B | Substituted azacycles as TRMP modulators | 奇华顿股份有限公司 | 2025-03-18 | — | — | CN | disclosed |
| US-12187735-B2 | Matter of composition, synthesis, formulation and application of FL118 platform positions 7 and 9-derived analogues for treatment of human disease | CANGET BIOTEKPHARMA LLC (US) | 2025-01-07 | — | — | US | disclosed |
| EP-4263676-B1 | METHODS AND SYSTEMS FOR PRODUCTION OF FURFURAL | SHELL INT RESEARCH (NL) | 2024-10-30 | — | — | EP | disclosed |
| EP-0445257-A1 | PYRIDINE DERIVATIVES AND A LIQUID CRYSTAL MEDIUM. | MERCK PATENT GMBH (DE) | 1991-09-11 | — | — | EP | disclosed |
| WO-1991004249-A1 | PYRIDINE DERIVATIVES AND A LIQUID CRYSTAL MEDIUM | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 1991-04-04 | — | — | WO | disclosed |
| EP-0199260-B1 | BORONIC ACID ADDUCTS OF TECHNETIUM-99M DIOXIME COMPLEXES | E.R. Squibb & Sons, Inc. (US) | 1989-12-06 | — | — | EP | disclosed |
| US-4705849-A | Boronic acid adducts of technetium-99m dioxime complexes | E. R. SQUIBB & SONS, INC. (US) | 1987-11-10 | — | — | US | disclosed |
| EP-0199260-A2 | Boronic acid adducts of technetium-99M dioxime complexes | E.R. Squibb & Sons, Inc. (US) | 1986-10-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12187735-B2 | Matter of composition, synthesis, formulation and application of FL118 platform positions 7 and 9-derived analogues for treatment of human disease | TP53, BRCA1, MET | SMN1; SMN2 499/4885CYP2C19 4533/4885TP53 1/4885 |
| US-20250282735-A1 | BICYCLE COMPOUNDS AS TEAD INHIBITOR | TEAD1, TEAD2, TEAD3 | SMN1; SMN2 3777/4885CYP2C19 33/4885TP53 948/4885 |
| US-20250092058-A1 | MATTER OF COMPOSITION, SYNTHESIS, FORMULATION AND APPLICATION OF FL 118 PLATFORM POSITIONS 7 AND 9-DERIVED ANALOGUES FOR TREATMENT OF HUMAN DISEASE | FLNA, FLNB, FLI1 | SMN1; SMN2 23/4885CYP2C19 4802/4885TP53 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.